billHR2936Event Thursday, April 17, 2025Analyzed

Addressing Boarding and Crowding in the Emergency Department

Neutral
Impact2/10

Summary

HR2936 (ABC-ED Act) authorizes zero new funding and remains in early committee stage with no near-term market impact. The bill expands eligibility for existing public health data modernization grants to include hospital bed capacity tracking at the state and regional level, but any fiscal effect requires separate appropriations.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR2936 authorizes zero new funding — it merely expands eligibility for existing grant programs
  • 2.Bill remains in early committee stage; no fiscal impact without separate appropriations
  • 3.No near-term market impact; no actionable tickers at this stage

Market Implications

No near-term market impact. The bill is a procedural authorization with zero funding at the earliest legislative stage. Retail investors should not base any trading decisions on this legislation. No tickers meet the causal chain threshold for inclusion.

Full Analysis

1) What happened and its current status: Representative John Joyce (R-PA) introduced HR2936 on April 17, 2025. The bill was referred to the House Committees on Energy and Commerce and Ways and Means. As of April 30, 2026, it remains in early committee stage with no further actions. A companion bill, S1974, exists in the Senate. 2) The money trail: The bill authorizes exactly zero new funding. It merely amends the Public Health Service Act to allow existing Sec. 2823 data modernization grants to be used for hospital bed capacity tracking. No money moves without a separate appropriations act. 3) Structural winners and losers: At this procedural stage, there are no direct winners or losers. If the bill were to advance with appropriations, health IT system vendors and state public health departments would be potential beneficiaries. However, with zero authorized dollars, even that link is speculative. 4) Timeline: The bill needs committee markup, House floor vote, Senate passage, and appropriations to have any fiscal impact. Near-term probability of enactment is negligible. 5) Market implications: None currently. No actionable trading thesis exists at this stage.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.